A Case Report of Follicular Lymphoma in a Crohn's Disease Patient Treated With Azathioprine.

Autor:	Kottavadakkeel N; Gastroenterology, Pilgrim Hospital Boston, United Lincolnshire Hospital National Health Services (NHS) Trust, Lincolnshire, GBR., Farzina R; Gastroenterology, Pilgrim Hospital Boston, United Lincolnshire Hospital National Health Services (NHS) Trust, Lincolnshire, GBR., Rajaram A; Gastroenterology and Hepatology, Aster Medcity, Kochi, IND.; Otolaryngology, Pilgrim Hospital Boston, United Lincolnshire Hospital National Health Services (NHS) Trust, Lincolnshire, GBR., Mannath S; Diabetes and Endocrinology, Pilgrim Hospital Boston, United Lincolnshire Hospital National Health Services (NHS) Trust, Lincolnshire, GBR., Sunil A; Gastroenterology, Pilgrim Hospital Boston, United Lincolnshire Hospital National Health Services (NHS) Trust, Lincolnshire, GBR.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Dec 20; Vol. 15 (12), pp. e50839. Date of Electronic Publication: 2023 Dec 20 (Print Publication: 2023).
DOI:	10.7759/cureus.50839
Abstrakt:	Inflammatory bowel disease (IBD) is an autoimmune disorder marked by chronic inflammation affecting the intestines. Crohn's disease (CD) and ulcerative colitis (UC) fall under the IBD umbrella, necessitating diverse treatments, including steroids, immunomodulators like 6-mercaptopurine (6-MP) and azathioprine (AZA), and biological agents. The prolonged use of immunomodulators, such as AZA, is associated with an elevated risk of developing lymphomas. This case report centers on a 77-year-old gentleman regularly monitored by Gastroenterology, undergoing long-term AZA therapy for CD management. He presented with palate swelling and acute-on-chronic back pain, diagnosed with follicular lymphoma in the palate with metastasis. Palliative radiotherapy was administered for the paraspinal lesion, and the patient is currently stable. In conclusion, this case underscores the importance of recognizing the heightened risk of neoplasms, especially lymphomas, in patients undergoing prolonged immunomodulator therapy. It emphasizes the need for a vigilant and comprehensive approach to patient care, transcending conventional paradigms. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Kottavadakkeel et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu